TLR4 and inflammatory bowel disease: In this study, we combined anti-inflammatory TDNs, ATP-responsive nano-scaffolds, and TLR4 pathway inhibitory aptamers to develop a drug-free HAMs system for the oral administration of targeted therapy for IBD.